IMRX vs. RPID, ADAG, ATOS, CNTX, PRQR, RGLS, MCRB, SCPH, CYBN, and RPTX
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Rapid Micro Biosystems (RPID), Adagene (ADAG), Atossa Therapeutics (ATOS), Context Therapeutics (CNTX), ProQR Therapeutics (PRQR), Regulus Therapeutics (RGLS), Seres Therapeutics (MCRB), scPharmaceuticals (SCPH), Cybin (CYBN), and Repare Therapeutics (RPTX). These companies are all part of the "medical" sector.
Rapid Micro Biosystems (NASDAQ:RPID) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Immuneering has a consensus price target of $13.50, indicating a potential upside of 871.22%. Given Rapid Micro Biosystems' higher possible upside, analysts clearly believe Immuneering is more favorable than Rapid Micro Biosystems.
52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 30.4% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Immuneering has a net margin of 0.00% compared to Immuneering's net margin of -224.73%. Immuneering's return on equity of -42.25% beat Rapid Micro Biosystems' return on equity.
Immuneering received 20 more outperform votes than Rapid Micro Biosystems when rated by MarketBeat users. Likewise, 61.54% of users gave Immuneering an outperform vote while only 26.67% of users gave Rapid Micro Biosystems an outperform vote.
In the previous week, Immuneering had 2 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 4 mentions for Immuneering and 2 mentions for Rapid Micro Biosystems. Immuneering's average media sentiment score of 1.44 beat Rapid Micro Biosystems' score of 0.30 indicating that Rapid Micro Biosystems is being referred to more favorably in the media.
Rapid Micro Biosystems has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.
Rapid Micro Biosystems has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500.
Summary
Rapid Micro Biosystems beats Immuneering on 9 of the 17 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
